|Bid||853.70 x 0|
|Ask||853.90 x 0|
|Day's Range||843.30 - 859.50|
|52 Week Range||640.30 - 904.90|
|Beta (3Y Monthly)||0.82|
|PE Ratio (TTM)||498.07|
|Forward Dividend & Yield||26.44 (3.12%)|
|1y Target Est||93.83|
Today we will run through one way of estimating the intrinsic value of AstraZeneca PLC (LON:AZN) by taking the...
Farxiga is the first of its class to be approved in the United States for this indication, Ruud Dobber, executive vice president of BioPharmaceuticals at AstraZeneca said. "This is promising news for the 30 million people living with type-2 diabetes in the United States, as heart failure is one of the earliest cardiovascular complications for them, before heart attack or stroke," Dobber said.
Investing.com -- AstraZeneca (LON:AZN) said Monday its Farxiga drug for reducing the risk of heart failure in type-2 diabetes patients had been approved for use in the U.S. by the Food and Drug Administration.
Benzinga has examined the prospects for many investor favorite stocks over the past week. Bullish calls included a second-tier telecom and a fast-casual restaurant leader. Bearish calls included beleaguered ...
AstraZeneca plc (NYSE: AZN ) and partner DAIICHI SANKYO/S ADR (OTC: DSNKY ) announced positive news Thursday on their HER-2 targeting antibody drug conjugate, or ADC. This should come as a relief for the ...
AstraZeneca Plc said on Thursday that the U.S. drug regulator will give a speedy review to its experimental breast cancer treatment, which could put the British drugmaker in direct competition with bigger rival Roche Holding AG. The U.S. Food and Drug Administration (FDA) accepted AstraZeneca's application and granted the treatment, trastuzumab deruxtecan, a priority review for the treatment of HER2-positive metastatic breast cancer, the drugmaker said.
LOS ANGELES , Oct. 14, 2019 /PRNewswire/ -- ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca ...
Paul Hudson is examining the organization from top to bottom with the goal of developing a strategy to put the company on the road to success Continue reading...
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the second quarter. We get to see hedge funds' thoughts towards the market and […]
(Bloomberg) -- Three researchers from the U.S. and Britain won a Nobel Prize for showing how cells sense and adapt to changing oxygen levels, a line of research that’s already led to the development of new drugs.Americans William Kaelin of the Dana-Farber Cancer Institute in Boston and Gregg Semenza of Baltimore’s Johns Hopkins Medicine, and Peter Ratcliffe of the Francis Crick Institute in London received this year’s award for physiology or medicine, the Nobel Assembly at the Karolinska Institute said Monday in a statement.“The seminal discoveries by this year’s Nobel laureates revealed the mechanism for one of life’s most essential adaptive processes,” the assembly said in the statement. “Their discoveries have also paved the way for promising new strategies to fight anemia, cancer and many other diseases.”Semenza and Ratcliffe separately studied the processes surrounding the sensing of oxygen, and found it was at work in virtually all the body’s tissues. Semenza worked in the 1990s on identifying a protein complex that binds to cells’ DNA in response to levels of oxygen in the environment.The complex, called hypoxia inducible factor, regulates production of red blood cells. The science behind it is the basis for an anemia drug codeveloped by AstraZeneca Plc and Fibrogen Inc. called roxadustat that was approved in China in December.Astra is just a few steps away from bringing the drug to patients, said Mene Pangalos, executive vice president of biopharmaceutical research and development, in an email. “This would never have been possible without early breakthroughs of this year’s Nobel winners,” he said.GlaxoSmithKline Plc has filed for Japanese approval of a drug based on the mechanism, called daprodustat. Kaelin’s work linked the same oxygen-regulating machinery to a role in cancer, which is also being mined for potential therapeutics.Annual prizes for achievements in physics, chemistry, medicine, peace and literature were established in the will of Alfred Nobel, the Swedish inventor of dynamite, who died in 1896. The total amount for each of the 2019 prizes is 9 million kronor ($909,000).(Updates with company comment in sixth paragraph)\--With assistance from John Lauerman.To contact the reporters on this story: Niklas Magnusson in Stockholm at firstname.lastname@example.org;Veronica Ek in Stockholm at email@example.comTo contact the editors responsible for this story: Jonas Bergman at firstname.lastname@example.org, ;Tasneem Hanfi Brögger at email@example.com, Eric PfannerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
British drugmaker AstraZeneca said on Friday that the U.S. Food and Drug Administration (FDA) has approved self-administration of its asthma treatment Fasenra which uses a pre-filled, single-use auto-injector pen. The move is a boost for the drugmaker's respiratory portfolio after the regulator earlier this week declined to approve AstraZeneca's combination therapy to treat smoker's lung, as it tries to catch up with domestic rival GlaxoSmithKline. "We can now offer Fasenra in an even more convenient way, giving U.S. healthcare providers and patients the option of administering Fasenra at home or in a doctor's office," Mene Pangalos, executive vice president of BioPharmaceuticals R&D said.
Gaithersburg’s Viela Bio Inc. began publicly trading Thursday on the Nasdaq. The clinical-stage biotech is offering 7.9 million shares of common stock priced at $19 per share, positioning the company to raise roughly $150 million. Viela (NASDAQ: VIE) is also giving underwriters the option to buy up to an additional 1.19 million shares at the initial public offering price for 30 days.
The Emeryville company says it has improved on the traditional way of delivering corrected copies of genes.
The extent of stockpiling ahead of a possible hard Brexit was on display in Tuesday in areas ranging from manufacturing data to a bakery’s results.
Stock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses...
European shares ended a three-day winning streak on Tuesday as investors were gripped by growth worries after poor U.S. manufacturing data fanned fears of slowing growth in the world's largest economy. The pan-European STOXX 600 index touched session lows, and closed down 1.3% after data showed U.S. manufacturing contracted for the second month in September, knocking U.S. stocks. This followed on from euro zone data that showed manufacturing activity contracting at its steepest rate in almost seven years.
AstraZeneca Plc said on Tuesday it would sell the global commercial rights for its drug to treat acid reflux to German pharmaceutical company Cheplapharm Arzneimittel GmbH for as much as $276 million. Cheplapharm will pay AstraZeneca about $243 million for Losec, a proton pump inhibitor developed by the British drugmaker. The global commercial rights being sold to Cheplapharm, for Losec (omeprazole) and its associated brands, excludes rights in China, Japan, the United States and Mexico, AstraZeneca said.
The U.S. Food and Drug Administration declined to approve AstraZeneca Plc's combination therapy to treat smoker's lung, the drugmaker said on Tuesday. AstraZeneca said that it will work closely with the FDA regarding next steps, including submitting results from an additional late-stage study, which was not completed at the time the marketing application was submitted to the health regulator. The therapy, PT010, was approved in Japan in June as a triple-combination therapy to relieve symptoms of chronic obstructive pulmonary disease (COPD), AstraZeneca said.
AstraZeneca presented results on Monday for a trial of its Lynparza drug against prostate cancer, which it hopes could lead to wider regulatory approval for the treatment for use against more forms of the disease. The British drugmaker, together with development partner Merck & Co, said Lynparza was shown to delay disease progression in an aggressive and difficult-to-treat type of prostate cancer by a median 3.8 months in the group most sensitive to the treatment. The data, presented at the annual conference of the European Society for Medical Oncology (ESMO) in Barcelona, adds to further promising results presented on Saturday at the conference that may lead to wider use in women suffering from ovarian cancer.
The study tested Lynparza in patients as an add-on to an already existing standard of care, bevacizumab, and was compared to a group of patients given bevacizumab alone. The treatment showed a statistically significant and clinically meaningful improvement in progression-free survival in women with newly diagnosed advanced ovarian cancer, the companies said. Lynparza added to bevacizumab reduced the risk of disease progression or death by 41% in the overall trial population.
AstraZeneca Plc and Merck & Co Inc said on Monday their treatment for newly diagnosed advanced ovarian cancer improved progression-free survival in patients tested in a late-stage study. The study tested Lynparza in patients as an add-on to an already existing standard of care, bevacizumab, and was compared to a group of patients given bevacizumab alone. The treatment showed a statistically significant and clinically meaningful improvement in progression-free survival in women with newly diagnosed advanced ovarian cancer, the companies said.
AstraZeneca Plc and Merck & Co Inc said on Monday their drug to treat a form of ovarian cancer improved progression-free survival in patients tested in a late-stage study. The study tested Lynparza in patients as an add-on to an already existing standard of care, bevacizumab, and was compared to a group of patients given bevacizumab alone. Lynparza added to bevacizumab reduced the risk of disease progression or death by 41% in the overall trial population.